Lamivudina Normon

Lamivudine, the active ingredient in Lamivudina Normon, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral administration. It is used in the management of HIV infection and chronic hepatitis B, helping to suppress viral replication in adult patients.

GNH USA supplies Lamivudina Normon as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with consistent quality and regulatory compliance.

Lamivudina Normon is a nucleoside reverse transcriptase inhibitor indicated for viral infections that rely on reverse transcription.

- HIV infection: reduces viral load and helps restore immune function. - Chronic hepatitis B: suppresses HBV DNA replication and reduces liver inflammation. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission during pregnancy and delivery.

Lamivudina Normon may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Fatigue: general tiredness without specific cause. - Diarrhea: loose stools that resolve with continued therapy.

Serious or Rare Side Effects: - Severe lactic acidosis: accumulation of lactate leading to metabolic disturbance. - Hepatic steatosis: fatty changes in the liver that may progress to dysfunction. - Hypersensitivity reactions: rash, fever, or organ involvement requiring medical attention.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: obtain baseline enzymes and repeat periodically. - Assess renal function: evaluate creatinine clearance for dose considerations. - Screen for hepatitis B co‑infection: monitor viral load and liver status. - Counsel on adherence: emphasize consistent daily dosing to maintain efficacy. - Store at ambient temperature: keep below 25°C, protect from moisture, and retain in the original packaging.

Lamivudina Normon can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis. - Stavudine: concurrent therapy raises the chance of peripheral neuropathy. - Zalcitabine: co‑administration may enhance mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Ribavirin: may add to hematologic suppression. - Efavirenz: can lower lamivudine plasma concentrations, requiring monitoring.